Skip to main content
Fig. 2 | BMC Immunology

Fig. 2

From: LncRNA CYP1B1-AS1 as a clinical biomarker exacerbates sepsis inflammatory response via targeting miR- 18a- 5p

Fig. 2

CYP1B1-AS1 levels may predict unfavorable outcomes in sepsis patients. A Serum CYP1B1-AS1 expression in death and survival patients with sepsis at 28 days of follow-up. B The ROC curve was employed to examine the predictive significance of serum CYP1B1-AS1 for mortality in sepsis patients. C Kaplan-Meier curves depicted cumulative survival rates, with group differences assessed by the log-rank test. **** P < 0.0001

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us